Ollin Biosciences Agrees To $2.2B J&J Sale | Up To $3.33B With Milestones

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2B upfront plus up to about $1.125B in milestones, adding OLN324, a bispecific eye drug it describes as Phase 3, as Blackstone funds $750M of its development.

Trace Cohen
By Trace Cohen · Value Add Pulse Funding Desk
Founder & Editor-in-chief, Value Add VC
3 min read
Ollin Biosciences Agrees To $2.2B J&J Sale | Up To $3.33B With Milestones: key figures
ShareXLinkedInEmail

THE RUNDOWN

1

ARCH Venture Partners and Mubadala Capital get a $2.2B upfront exit from a company that was founded in 2023, per CNBC.

2

The sale comes five months after Ollin's $330M Series B, when Dealroom lists its valuation at $1.3B, a quick markup for late-stage investors.

3

Blackstone will pay J&J $750M over several years toward OLN324's development, so the buyer shares the Phase 3 cost with a private-capital partner.

4

OLN324 aims at the retina market Roche's Vabysmo leads, and Ollin says an early head-to-head study beat Vabysmo on eye structure and vision gains.

The VC Read

Value Add VC analysis

Our read: the Blackstone money is the real structure here. J&J pays $2.2B upfront, then Blackstone hands back $750M over several years for development in exchange for milestones and single-digit royalties, which by our arithmetic leaves J&J about $1.45B after that funding, before discounting the multi-year payments and the milestones and royalties J&J cedes and turns part of the Phase 3 risk into a royalty bet. For biotech founders, that template matters more than the price: this deal suggests buyers may be able to stretch to a bigger upfront when a fund carries part of the trial bill. The diligence item is the head-to-head claim against Vabysmo, which comes from an early-stage study reported by Ollin.

Analysis

Ollin Biosciences has agreed to be acquired by Johnson & Johnson for $2.2 billion upfront, with regulatory and commercial milestone payments of up to approximately $1.125 billion on top, J&J said on November 16, 2026 in a press release.

CNBC puts the total at up to $3.33 billion. The deal brings J&J OLN324, which J&J describes as a Phase 3 investigational bispecific antibody for retinal vascular diseases, and is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.

A second agreement sits alongside the purchase. Blackstone will pay J&J a total of $750 million over multiple years toward OLN324's development, and in return is eligible for regulatory and sales milestones and single-digit royalties, per the J&J release. That funding only kicks in if the acquisition closes. J&J said the accounting treatment will be communicated on or before closing.

“CNBC puts the total at up to $3.33 billion.”

What Ollin Biosciences does

Ollin is a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. CNBC describes it as a Texas-based biotech established in 2023; Dealroom lists its headquarters as Austin and names co-founder Jason Ehrlich as chief executive. Its lead drug, OLN324, targets two pathways at once, VEGF and Ang2, in a small antibody format J&J calls a minibody, and is being developed for wet age-related macular degeneration and diabetic macular edema. Kip Connor, who leads J&J's ophthalmology disease area, said in the release that the drug could cut retinal fluid more effectively and allow more time between treatments.

How much has Ollin Biosciences raised?

CNBC reports that Ollin raised $330 million in June to fund its trials, the round Pulse covered at the time. Dealroom's company profile adds the earlier round and the marks.

Value Add VC data

  • Sep 2025, Series A -- $100M at a $400M valuation, led by ARCH Venture Partners, Mubadala Capital and Monograph Capital (Dealroom)
  • Jun 2026, Series B -- $330M at a $1.3B valuation, lead not listed (Dealroom; amount confirmed by CNBC)
  • Nov 2026, acquisition -- $2.2B upfront plus up to about $1.125B in milestones, buyer Johnson & Johnson (J&J)

On those figures, the $2.2 billion upfront price is about 1.7 times the $1.3 billion Series B valuation Dealroom lists, and the full $3.33 billion with milestones would be about 2.6 times, five months after that round.

Who invested in Ollin Biosciences?

CNBC names ARCH Venture Partners and Mubadala Capital as Ollin's backers. Dealroom lists ARCH, Mubadala Capital and Monograph Capital as leads of the first $100 million, and Blackstone, CPP Investments, Mubadala Capital and a16z Bio + Health among Series B investors. If Dealroom's list is right, Blackstone sits on both sides of Monday's deal: a Series B investor in Ollin and now J&J's development-funding partner. See our Ollin Biosciences hub for prior coverage.

Retina drug market and competitors

OLN324 is aimed at a market Roche's Vabysmo, itself a VEGF and Ang2 bispecific, already serves. CNBC reports that in an early-stage head-to-head study, OLN324 showed faster and greater improvements in eye structure and greater vision gains than Vabysmo, according to Ollin. Blackstone's life sciences arm has used the same funding playbook before: CNBC notes Pfizer's separate deal with Blackstone for up to $1.5 billion.

The caveat is the evidence. The comparison with Vabysmo comes from an early study reported by the company, not from Phase 3 data, and CNBC says late-stage studies were planned to start in the second half of this year. J&J is paying $2.2 billion for a drug whose pivotal late-stage trials have not yet read out, and roughly a third of the headline value depends on milestones that only pay if OLN324 is approved and sells.

ShareXLinkedInEmail

More from the Pulse archive: Startup & VC Funding coverage → · All topics

Key Sources

1 source

THE WIRE in your inbox— Tech, startup & VC news with The VC Read, a few times a week. Free to subscribe, no spam.

No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗